EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study

Hans C Lee iD, Karthik Ramasamy iD, Margaret Macro, Faith E Davies, Rafat Abonour, Frits van Rhee, Vania T M Hungria, Noemi Puig, Kaili Ren, Jiri Silar, Victoria Enwemadu, Dasha Cherepanov und 1 weitere

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14214 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Verfasst von Hans C Lee und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Boron Compounds, Glycine, Lenalidomide. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AHRQ HHS, Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To characterize the impact of prior exposure and refractoriness to lenalidomide or proteasome inhibitors (PIs) on the effectiveness and safety of ixazomib–lenalidomide–dexamethasone (IRd) in relapsed/refractory multiple myeloma (RRMM).

Methods

INSURE is a pooled analysis of adult RRMM patients who had received IRd in ≥2 line of therapy from three studies: INSIGHT MM, UVEA‐IXA, and REMIX.

Results

Overall, 391/100/68 were lenalidomide‐naïve/−exposed/−refractory and 37/411/110 were PI‐naïve/−exposed/−refractory. Median duration of therapy (DOT) was 15.3/15.6/4.7 months and median progression‐free survival (PFS) was 21.6/25.8/5.6 months in lenalidomide‐naïve/exposed/refractory patients. Median DOT and PFS in PI‐naïve/exposed/refractory patients were 20.4/15.2/6.9 months and not reached/19.8/11.4 months, respectively. The proportion of lenalidomide‐naïve/exposed/refractory patients in INSIGHT and UVEA‐IXA who discontinued a study drug due to adverse events (AEs) was ixazomib, 31.6/28.2/28.0% and 18.6/6.7/10.5%; lenalidomide, 21.9/28.2/16.0% and 16.1/6.7/10.5%; dexamethasone, 18.4/20.5/16.0% and 10.6/0/10.5%, respectively. The proportion of PI‐naïve/exposed/refractory patients in INSIGHT and UVEA‐IXA who discontinued a study drug due to AEs was: ixazomib, 44.4/28.8/27.8% and 22.2/16.7/15.7%; lenalidomide, 33.3/22.0/19.4% and 16.7/15.9/11.8%; dexamethasone, 33.3/17.4/16.7% and 16.7/9.5/7.8%, respectively. REMIX AE discontinuation rates were unavailable.

Conclusion

IRd appeared to be effective in RRMM patients in routine clinical practice regardless of prior lenalidomide or PI exposure, with better outcomes seen in lenalidomide‐ and/or PI‐nonrefractory versus refractory patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaBoron CompoundsGlycineLenalidomideDexamethasoneAntineoplastic Combined Chemotherapy ProtocolsProteasome InhibitorsDrug Resistance, NeoplasmHumansMaleAgedFemaleMiddle AgedTreatment OutcomeAdultAged, 80 and overRecurrenceRetreatment

Stichwörter der Autor:innen

effectivenessixazomiblenalidomidemultiple myelomaprior treatment exposureproteasome inhibitorrelapsed/refractory

Substanzen

Boron CompoundsGlycineixazomibLenalidomideDexamethasoneProteasome Inhibitors

Autor:innen und Institutionen

  • Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, UK.
  • CHU de Caen Normandie, Caen, France.
  • Perlmutter Cancer Center, NYU Langone, New York City, New York, USA.
  • Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas, USA.

ORCID-Profile: Hans C Lee, Karthik Ramasamy

Förderung

  • AHRQ HHS
  • Takeda Development Center Americas, Inc. (TDCA), Lexington, MA, USA

Zitieren

APA

Lee, H. C., Ramasamy, K., Macro, M., Davies, F. E., Abonour, R., van Rhee, F., Hungria, V. T. M., Puig, N., Ren, K., Silar, J., Enwemadu, V., Cherepanov, D., & Leleu, X. (2024). Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study. European Journal of Haematology. https://doi.org/10.1111/ejh.14214

Vancouver

Lee HC, Ramasamy K, Macro M, Davies FE, Abonour R, van Rhee F, et al. Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study. European Journal of Haematology. 2024. doi:10.1111/ejh.14214

BibTeX
@article{Lee2024,
  author = {Lee, Hans C and Ramasamy, Karthik and Macro, Margaret and Davies, Faith E and Abonour, Rafat and van Rhee, Frits and Hungria, Vania T M and Puig, Noemi and Ren, Kaili and Silar, Jiri and Enwemadu, Victoria and Cherepanov, Dasha and Leleu, Xavier},
  title = {Impact of prior lenalidomide or proteasome inhibitor exposure on the effectiveness of ixazomib–lenalidomide–dexamethasone for relapsed/refractory multiple myeloma: A pooled analysis from the INSURE study},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14214}
}
Kostenlos starten →